Sclerotherapy Market by Agents (Detergents, Chemical Irritants, and Osmotic Agents), Types (Ultrasound Sclerotherapy, Liquid Sclerotherapy, and Foam Sclerotherapy), Applications Types (Venous Disease, Gastrointestinal Bleeding, Bronchopleural Fistula, Cystic Disease, Systemic Diseases), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast, 2021-2028
The global sclerotherapy market size was valued at USD 848.8 million in 2019 and is anticipated to grow at a CAGR of 5.6% from 2021 to 2028. Growing geriatric population, rising incidence of varicose veins, technological advancements pertaining to venous diseases, and growing demand for minimally invasive procedures are driving the market. Introduction of ultrasound-guided sclerotherapy and foam sclerotherapy has enabled practitioners to carry out these procedures in the underlying veins with precision and care.
Sclerotherapy is a minimally invasive procedure used for the treatment of spider veins or varicose veins and involves injecting the veins with sclerosing agents like detergents, chemicals, and osmotic agents. It causes shrinking of the veins and reduces the damage.
Market Trends, Drivers, Restraints, and Opportunities:
- Growing prevalence of thrombotic disorders leads to stroke or mesenteric ischemia, which drives the sclerotherapy market.
- Recent advancements in cardiology such as revascularization and cardiogenic shock is likely to boost the sclerotherapy market.
- Rising incidence of varicose veins drives the sclerotherapy market.
- Complications in dermatological procedures such as bleeding and infection increases pain and discomfort and delays the healing process. This factor is likely to hamper the growth of the sclerotherapy market.
- Treatment may cause matting, scarring, and allergic reactions in some patients, which might hinder the market growth.
- Advent of advanced treatment options for varicose veins such as endovenous laser ablation, radiofrequency ablation, conventional operation, and subfascial endoscopic perforator surgery are expected to hinder the market growth.
- Technical advancement in the field of sclerotherapy such as cryotherapy, which delivers cold air into the skin leading to a pain-free process, acts as an opportunity for the sclerotherapy market.
Scope of Sclerotherapy Market Report
The report on acupuncture needles market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have been included in the report.
|
Attributes |
Details |
|
Report Title |
Sclerotherapy Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018-2019 |
|
Forecast Period |
2021-2028 |
|
Segmentation |
Agents (Detergents, Chemical Irritants, and Osmotic Agents), Types (Ultrasound Sclerotherapy, Liquid Sclerotherapy, and Foam Sclerotherapy), Applications (Venous Disease, Gastrointestinal Bleeding, Bronchopleural Fistula, Cystic Disease, Systemic Diseases) |
|
Regional Scope |
Asia Pacific, North America, Europe, Latin America, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players |
Boston Scientific Corporation, Chemische Fabrik Kreussler & Co. GmbH, LGM Pharma, TIANYU CHANG’AN GROUP, and AngioDynamics. |
Sclerotherapy Market Segment Insights:
Detergents Segment held a substantial market share during the forecast period
Based on agents, the sclerotherapy market is fragmented into detergents, chemical irritants, and osmotic agents. The detergents segment held a substantial market share of 42.0% in 2019 and is expected to witness a high CAGR during the forecast period. Detergents sclerosing agents are used to treat spider telangiectasias in various concentrations ranging from 0.05% to 0.5%. Detergents work by a mechanism known as protein theft denaturation, which causes endothelial damage or desquamation of endothelial cells in plaques through interference with cell surface lipids. Common types of detergents are Sodium Morrhuate (SM), Ethanolamine Oleate (EO), Sodium Tetradecyl Sulphate (Sotradecol), Polidocanol, and Scleremo.
Liquid Sclerotherapy is Expected to Occupy a Significant Share over the Forecast Period
On the basis of types, the sclerotherapy market is segmented into ultrasound sclerotherapy, liquid sclerotherapy, and foam sclerotherapy. The liquid sclerotherapy segment held a high market share of 38.0% in 2019 and is anticipated to witness a significant CAGR during the forecast period. Foam sclerotherapy is based on the air-block technique, wherein a small bubble of air is injected into the target vessel and the sclerosant is injected in the center of the bubble.
A foam with detergent sclerosants allows efficient sclerosant effect by increasing both contact area and dwell time and minimizing the admixture of sclerosant and blood. Increasing efficiency allows low sclerosants doses. Ultrasound-guided foam sclerotherapy is an upcoming therapy, which allows doctors to monitor the effect of each injection while ensuring the safety of all adjacent structures. It is effective as compared to a liquid therapy.
North America is Expected to Dominate the Sclerotherapy Myomectomy Market Over the Forecast Period
On the basis of regions, the sclerotherapy market is split into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is dominating the market and accounts for a revenue share of 46.1% in 2019. The market in North America is expected to witness a significant CAGR during the forecast period, due to increasing R&D investments and presence of global players. As per the Society of Vascular Surgery, more than 33.0% of women and about 17.0% of men consulted a doctor for telangiectasias and varicose veins in industrialized countries, affecting up to 35.0% of people in the US and Europe.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Sclerotherapy Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Sclerotherapy Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Sclerotherapy Market - Supply Chain
4.5. Global Sclerotherapy Market Forecast
4.5.1. Sclerotherapy Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Sclerotherapy Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Sclerotherapy Market Absolute $ Opportunity
5. Global Sclerotherapy Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Sclerotherapy Market Size and Volume Forecast by Types
5.3.1. Ultrasound Sclerotherapy
5.3.2. Liquid Sclerotherapy
5.3.3. Foam Sclerotherapy
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Sclerotherapy Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Sclerotherapy Market Size and Volume Forecast by Applications
6.3.1. Venous Disease
6.3.2. Gastrointestinal Bleeding
6.3.3. Bronchopleural Fistula
6.3.4. Cystic Disease
6.3.5. Systemic Diseases
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Sclerotherapy Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Sclerotherapy Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Sclerotherapy Demand Share Forecast, 2019-2026
8. North America Sclerotherapy Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Sclerotherapy Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Sclerotherapy Market Size and Volume Forecast by Types
8.4.1. Ultrasound Sclerotherapy
8.4.2. Liquid Sclerotherapy
8.4.3. Foam Sclerotherapy
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Sclerotherapy Market Size and Volume Forecast by Applications
8.7.1. Venous Disease
8.7.2. Gastrointestinal Bleeding
8.7.3. Bronchopleural Fistula
8.7.4. Cystic Disease
8.7.5. Systemic Diseases
8.8. Basis Point Share (BPS) Analysis by Applications
8.9. Y-o-Y Growth Projections by Applications
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Sclerotherapy Demand Share Forecast, 2019-2026
9. Latin America Sclerotherapy Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Sclerotherapy Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Sclerotherapy Market Size and Volume Forecast by Types
9.4.1. Ultrasound Sclerotherapy
9.4.2. Liquid Sclerotherapy
9.4.3. Foam Sclerotherapy
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Sclerotherapy Market Size and Volume Forecast by Applications
9.7.1. Venous Disease
9.7.2. Gastrointestinal Bleeding
9.7.3. Bronchopleural Fistula
9.7.4. Cystic Disease
9.7.5. Systemic Diseases
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Sclerotherapy Demand Share Forecast, 2019-2026
10. Europe Sclerotherapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Sclerotherapy Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Sclerotherapy Market Size and Volume Forecast by Types
10.4.1. Ultrasound Sclerotherapy
10.4.2. Liquid Sclerotherapy
10.4.3. Foam Sclerotherapy
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Sclerotherapy Market Size and Volume Forecast by Applications
10.7.1. Venous Disease
10.7.2. Gastrointestinal Bleeding
10.7.3. Bronchopleural Fistula
10.7.4. Cystic Disease
10.7.5. Systemic Diseases
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Sclerotherapy Demand Share Forecast, 2019-2026
11. Asia Pacific Sclerotherapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Sclerotherapy Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Sclerotherapy Market Size and Volume Forecast by Types
11.4.1. Ultrasound Sclerotherapy
11.4.2. Liquid Sclerotherapy
11.4.3. Foam Sclerotherapy
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Sclerotherapy Market Size and Volume Forecast by Applications
11.7.1. Venous Disease
11.7.2. Gastrointestinal Bleeding
11.7.3. Bronchopleural Fistula
11.7.4. Cystic Disease
11.7.5. Systemic Diseases
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Sclerotherapy Demand Share Forecast, 2019-2026
12. Middle East & Africa Sclerotherapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Sclerotherapy Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Sclerotherapy Market Size and Volume Forecast by Types
12.4.1. Ultrasound Sclerotherapy
12.4.2. Liquid Sclerotherapy
12.4.3. Foam Sclerotherapy
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Sclerotherapy Market Size and Volume Forecast by Applications
12.7.1. Venous Disease
12.7.2. Gastrointestinal Bleeding
12.7.3. Bronchopleural Fistula
12.7.4. Cystic Disease
12.7.5. Systemic Diseases
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Sclerotherapy Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Sclerotherapy Market: Market Share Analysis
13.2. Sclerotherapy Distributors and Customers
13.3. Sclerotherapy Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Boston Scientific Corporation
13.4.2. Chemische Fabrik Kreussler & Co. GmbH
13.4.3. LGM Pharma
13.4.4. TIANYU CHANG’AN GROUP
13.4.5. AngioDynamics